Altogether, we propose here a unique liver disease signature for HT1 under NTBC treatment comprising 25 genes (excluding Fah and Hgd), which indicates that NTBC therapy does not necessarily completely resolves HT1-driven liver disease or completely abolishes the risk to develop HCC over time. Here, FAH is linked to liver disorder.